%0 Journal Article
%A Dinkel, Hendrik
%A Materna, Linus
%A Stelmach, Ramona
%A Zschäbitz, Stefanie
%A Neuberger, Stephanie
%A Aydogdu, Can D
%A Casuscelli, Jozefina
%A Egenolf, Timo
%A Silberg, Matteo
%A Steinestel, Julie
%A Strauss, Arne
%A Kirchhoff, Florian
%A Ahrens, Marit
%A Paffenholz, Pia
%A Cathomas, Richard
%A Özdemir, Berna C
%A Gossler, Christopher
%A Ivanyi, Philipp
%A Rehlinghaus, Marc
%A Hilser, Thomas
%A Grünwald, Viktor
%A Schlack, Katrin
%T Real-world efficacy and toxicity of ipilimumab and nivolumab as a first-line treatment for advanced renal cell carcinoma according to IMDC risk criteria-A multi-center retrospective analysis on behalf of the GUARDIANS group.
%J International journal of cancer
%V nn
%@ 0020-7136
%C Bognor Regis
%I Wiley-Liss
%M DKFZ-2025-02666
%P nn
%D 2025
%Z epub
%X Ipilimumab and nivolumab are recommended as first-line therapy for patients with metastatic or advanced renal cell carcinoma (aRCC) and International Metastatic RCC Database Consortium (IMDC) intermediate or poor risk. We retrospectively evaluated efficacy and safety in a multi-center real-world cohort with 356 patients initiating ipilimumab and nivolumab from 17 centers in Germany and Switzerland. Median age was 64 years, most patients were male (69.1
%K immunotherapy (Other)
%K ipilimumab (Other)
%K nivolumab (Other)
%K real‐world (Other)
%K renal cell carcinoma (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:41317031
%R 10.1002/ijc.70267
%U https://inrepo02.dkfz.de/record/306673